Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential

Biogen (BIIB) is back in focus after Eisai and the company shared new real-world data at AD/PD 2026, showing that many patients remain on Alzheimer’s drug lecanemab beyond the initial 18-month treatment period.

See our latest analysis for Biogen.

Despite the positive lecanemab and pipeline headlines in recent weeks, Biogen’s share price has eased, with a 1-month share price return of a 5.5% decline and a 7-day return of a 1% decline, while the 1-year total shareholder return of 28.15% contrasts with weaker 3- and 5-year total shareholder returns.

If this Alzheimer’s readthrough has you thinking about where else biotech and health-related AI could reshape treatment, it may be worth scanning 36 healthcare AI stocks.

With Biogen trading at US$181.46 alongside mixed recent returns and an implied discount to some valuation models, the key question for you is whether current levels reflect a genuine mispricing or if markets already expect future growth.

Most Popular Narrative: 11.8% Undervalued

Biogen’s most followed narrative pegs fair value at about $205.67, above the last close of $181.46, and ties that gap directly to how its pipeline and margins evolve.

Enhancements in operational efficiency through ongoing "Fit for Growth" initiatives, disciplined cost management, and portfolio prioritization are expected to improve cost control, drive higher net margins over time, and support stronger earnings. Robust late-stage and diversified neurodegenerative and specialty disease pipelines including Phase III launches in SMA, lupus, and kidney indications capitalize on regulatory momentum to address high unmet needs, creating multiple shots on goal that reduce future revenue volatility and support long-term earnings stability.

Read the complete narrative.

Curious what has to happen for that valuation gap to close? The narrative leans on a specific mix of margin gains, pipeline execution and a future earnings multiple that investors usually reserve for more fully proven franchises.

Result: Fair Value of $205.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still meaningful risk if newer launches like LEQEMBI, SKYCLARYS or ZURZUVAE underperform expectations, or if competition in MS and Alzheimer’s intensifies faster than anticipated.

Find out about the key risks to this Biogen narrative.

Next Steps

Sensing mixed sentiment from the story so far? Take a closer look at the full picture yourself by weighing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Biogen has your attention, do not stop here, fresh opportunities across sectors could fit your style better and you will not want to miss them.

• Target sturdier balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (39 results) that pair financial resilience with proven fundamentals.
• Seek stronger value potential by reviewing the 54 high quality undervalued stocks built to spotlight companies with quality fundamentals at compressed prices.
• Line up reliable income ideas by checking the 13 dividend fortresses featuring businesses with higher yields that may interest long term holders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com